AZ's R&D information chief eyes improved trial success

AstraZeneca ($AZN) has plenty to learn from clinical trials that ended in failure, and the company has turned to many different new computer technologies to streamline its R&D efforts and boost efficiency in drug development. In a wide-ranging interview with Bio-IT World, John Reynders, head of R&D information, commented on the solutions on the table to increase the chances of triumphing in mid- and late-stage clinical trials. "We're also looking at translational informatics, segmentation analytics, biomarker platforms, how can we bring to bear all that insight into patient populations," he said. Q&A